| Trial ID: | L7316 |
| Source ID: | NCT00397553
|
| Associated Drug: |
Insulin Glulisine
|
| Title: |
Insulin Glulisine, Diabetes Mellitus Type 1
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: Insulin glulisine
|
| Outcome Measures: |
Primary: HbA1c, 52 weeks | Secondary: HbA1c, 26 weeks|Fasting Blood Glucose, 26 weeks|Fasting Blood Glucose, 52 weeks|Post-prandial glycemia (2 hour after breakfast), 26 weeks|Post-prandial glycemia (2 hour after breakfast), 52 weeks
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
104
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-01
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2009-09-18
|
| Locations: |
Sanofi-Aventis, Moscow, Russian Federation
|
| URL: |
https://clinicaltrials.gov/show/NCT00397553
|
